GlassScriptPhysician profile
Ioannis Chatzizisis
NPI 1528406097
$191,604.35
in general payments reported to CMS, 2019-2025
22 companies · $3,692 in 2025
The $3,692 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $5,634 · 2021: $38K · 2022: $14K · 2023: $104K · 2024: $3,753 · 2025: $3,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Consulting Fee: $39K · Food and Beverage: $6,893 · Travel and Lodging: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,529.54 |
| Consulting Fee | $39,375.00 |
| Food and Beverage | $6,893.43 |
| Travel and Lodging | $3,016.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $109,127.23 | 2019-2025 | Avvigo Guidance System, Sentinel, Emerge Push |
| Medtronic, INC. | $71,135.93 | 2021-2025 | Onyx Frontier, Symplicity G3, Pulseselect |
| Medtronic Vascular, INC. | $3,487.23 | 2019-2020 | |
| Heartflow, INC. | $3,379.94 | 2023-2025 | Ffrct |
| Siemens Medical Solutions USA, INC. | $1,513.88 | 2022-2023 | Artis Icono Biplane, Naeotom Alpha |
| Penumbra, INC. | $725.03 | 2023-2024 | Indigo System, Penumbra System |
| Teleflex LLC | $639.43 | 2025 | Manta, Guideliner |
| Abbott Laboratories | $493.92 | 2023-2025 | Amplatzer Amulet, Coroflow, Pressurewire |
| Shockwave Medical, INC | $337.90 | 2020-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Circulation INC | $147.60 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Astrazeneca Pharmaceuticals LP | $114.46 | 2025 | Farxiga |
| Tersera Therapeutics LLC | $109.31 | 2023 | Xermelo |
| Alnylam Pharmaceuticals INC. | $89.19 | 2024 | Amvuttra |
| Chiesi USA, INC. | $72.00 | 2023 | Kengreal |
| Philips North America LLC | $58.82 | 2025 | Coronary Other |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $57.88 | 2024 | Paradise Renal Denervation System |
| Esaote North America, INC. | $30.04 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $29.27 | 2025 | Uptravi, Opsumit |
| Spectrawave, INC | $21.07 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.21 | 2020 | |
| Kestra Medical Technology Services, INC. | $17.01 | 2024 | Assure Wcd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioannis Chatzizisis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.